Literature DB >> 16453003

AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.

L-Y Shih1, D-C Liang, C-F Huang, J-H Wu, T-L Lin, P-N Wang, P Dunn, M-C Kuo, T-C Tang.   

Abstract

The roles of CEBPalpha mutations and its cooperating mutations in the relapse of acute myeloid leukemia (AML) are not clear. CEBPalpha mutations were analyzed on 149 patients with de novo AML at both diagnosis and relapse. Twenty-two patients (14.8%) had the mutations at diagnosis, two patients had N-terminal nonsense mutations alone, one had homozygous inframe duplication at the bZIP domain, and 19 patients had both N-terminal and bZIP mutations. Twenty patients relapsed with identical mutant patterns, two lost CEBPalpha mutations and none acquired the mutations at relapse. Cloning analysis showed that the N-terminal and C-terminal mutations occurred on separate cloned alleles and also on the same alleles in most of the diagnosis and relapse samples. Losing one of the two or more mutations on the same allele or acquiring the other mutation on the allele original carrying single mutation were observed not infrequently in the paired samples analyzed. Seven patients with CEBPalpha mutations had cooperating mutations with FLT3/ITD, FLT3/TKD or N-ras but not K-ras mutations. Our study showed that 91% of de novo AML harboring CEBPalpha mutations at diagnosis retained the identical mutant patterns but frequently changed in the allelic distribution at relapse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453003     DOI: 10.1038/sj.leu.2404124

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia.

Authors:  Kristian Reckzeh; Jörg Cammenga
Journal:  Int J Hematol       Date:  2010-04-27       Impact factor: 2.490

3.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.

Authors:  John A Pulikkan; Philomina S Peramangalam; Viola Dengler; Phoenix A Ho; Claude Preudhomme; Soheil Meshinchi; Maximilian Christopeit; Oliver Nibourel; Carsten Müller-Tidow; Stefan K Bohlander; Daniel G Tenen; Gerhard Behre
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

4.  FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.

Authors:  Katharina Wagner; Frederik Damm; Felicitas Thol; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

Review 5.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

Review 6.  Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Authors:  Ashley Pandolfi; Laura Barreyro; Ulrich Steidl
Journal:  Stem Cells Transl Med       Date:  2013-01-24       Impact factor: 6.940

Review 7.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

8.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica Pollard; Derek L Stirewalt; Craig Hurwitz; Nyla A Heerema; Betsy Hirsch; Susana C Raimondi; Beverly Lange; Janet L Franklin; Jerald P Radich; Soheil Meshinchi
Journal:  Blood       Date:  2009-03-20       Impact factor: 22.113

9.  Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.

Authors:  O Quintana-Bustamante; S Lan-Lan Smith; E Griessinger; Y Reyal; J Vargaftig; T A Lister; J Fitzgibbon; D Bonnet
Journal:  Leukemia       Date:  2012-02-10       Impact factor: 11.528

Review 10.  Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.

Authors:  Hubert Hackl; Ksenia Astanina; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2017-02-20       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.